<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30364524</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1945-7928</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>2018</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Apr</Month>                    </PubDate>                </JournalIssue>                <Title>Proceedings. IEEE International Symposium on Biomedical Imaging</Title>                <ISOAbbreviation>Proc IEEE Int Symp Biomed Imaging</ISOAbbreviation>            </Journal>            <ArticleTitle>A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU.</ArticleTitle>            <Pagination>                <MedlinePgn>796-799</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1109/ISBI.2018.8363692</ELocationID>            <Abstract>                <AbstractText>Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Gray</LastName>                    <ForeName>Elliot</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering and Computational Biology Program.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mitchell</LastName>                    <ForeName>Elizabeth</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cell, Developmental and Cancer Biology Oregon Health &amp; Science University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jindal</LastName>                    <ForeName>Sonali</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cell, Developmental and Cancer Biology Oregon Health &amp; Science University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schedin</LastName>                    <ForeName>Pepper</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cell, Developmental and Cancer Biology Oregon Health &amp; Science University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chang</LastName>                    <ForeName>Young Hwan</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering and Computational Biology Program.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>U54 CA209988</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>05</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Proc IEEE Int Symp Biomed Imaging</MedlineTA>            <NlmUniqueID>101492570</NlmUniqueID>            <ISSNLinking>1945-7928</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Apr 25;7:46732</RefSource>                <PMID Version="1">28440283</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anal Quant Cytol Histol. 2001 Jun;23(3):218-28</RefSource>                <PMID Version="1">11444192</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Pathol. 2015 Nov;185(11):3076-89</RefSource>                <PMID Version="1">26343330</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2005 May 1;103(9):1778-84</RefSource>                <PMID Version="1">15770688</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>IEEE Trans Biomed Eng. 2014 Jun;61(6):1729-38</RefSource>                <PMID Version="1">24845283</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72</RefSource>                <PMID Version="1">16807805</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Methods. 2014 Nov;70(1):46-58</RefSource>                <PMID Version="1">25242720</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Clin Oncol. 2014 Aug 10;5(3):382-92</RefSource>                <PMID Version="1">25114853</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Rep. 2017 Apr 4;19(1):203-217</RefSource>                <PMID Version="1">28380359</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Aug 29;7(1):9900</RefSource>                <PMID Version="1">28852119</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2005;7(5):190-7</RefSource>                <PMID Version="1">16168137</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47</RefSource>                <PMID Version="1">16807803</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Biosci (Landmark Ed). 2010 Jan 01;15:226-36</RefSource>                <PMID Version="1">20036817</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>IEEE Trans Pattern Anal Mach Intell. 2012 Nov;34(11):2274-82</RefSource>                <PMID Version="1">22641706</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">DCIS</Keyword>            <Keyword MajorTopicYN="N">calponin</Keyword>            <Keyword MajorTopicYN="N">feature engineering</Keyword>            <Keyword MajorTopicYN="N">invasive breast cancer</Keyword>            <Keyword MajorTopicYN="N">myoepithelial cell</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30364524</ArticleId>            <ArticleId IdType="doi">10.1109/ISBI.2018.8363692</ArticleId>            <ArticleId IdType="pmc">PMC6196724</ArticleId>            <ArticleId IdType="mid">NIHMS992130</ArticleId>        </ArticleIdList>        <?nihms?>    </PubmedData></PubmedArticle></PubmedArticleSet>